Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects

387

1.

388

pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic

389

background. Acta Derm Venereol. 1996 Jan;76(1):68-71.

390

2.

391

for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese

392

population. Br J Dermatol. 2019 Feb;180(2):425-6.

393

3.

394

with the disease severity of generalized pustular psoriasis. Dis Markers. 2013;34(3):153-61.

395

4.

396

36 Activity Promotes Clonal CD4(+) T-Cell Responses with IL-17A Production in Generalized

397

Pustular Psoriasis. J Invest Dermatol. 2018 Jun;138(6):1338-47.

398

5.

399

receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011 Aug

400

18;365(7):620-8.

401

6.

402

Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease

403

known as generalized pustular psoriasis. Am J Hum Genet. 2011 Sep 9;89(3):432-7.

404

7.

405

factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest

406

Dermatol. 2014 Jun;134(6):1755-7.

407

8.

408

CARD14 Mutations Are Associated With Generalized Pustular Psoriasis but Rarely Account for

409

Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol. 2015 Jul 23.

410

9.

411

dominant familial generalized pustular psoriasis caused by a CARD14 mutation. Br J Dermatol.

412

2017 Oct;177(4):e133-e5.

413

10.

414

mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J

415

Hum Genet. 2014 May 1;94(5):790-7.

416

11.

417

morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a

418

tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014 Jun;53(6):676-84.

419

12.

420

Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34

421

patients. Am J Clin Dermatol. 2011 Aug 1;12(4):271-6.

Ohkawara A, Yasuda H, Kobayashi H, Inaba Y, Ogawa H, Hashimoto I, et al. Generalized

Li L, You J, Fu X, Wang Z, Sun Y, Liu H, et al. Variants of CARD14 are predisposing factors

Yamamoto M, Imai Y, Sakaguchi Y, Haneda T, Yamanishi K. Serum cytokines correlated

Arakawa A, Vollmer S, Besgen P, Galinski A, Summer B, Kawakami Y, et al. Unopposed IL-

Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-

Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al.

Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk

Berki DM, Liu L, Choon SE, David Burden A, Griffiths CE, Navarini AA, et al. Activating

Takeichi T, Kobayashi A, Ogawa E, Okuno Y, Kataoka S, Kono M, et al. Autosomal

Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu HC, Allen MH, et al. AP1S3

Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile,

Borges-Costa J, Silva R, Goncalves L, Filipe P, Soares de Almeida L, Marques Gomes M.

25

26

422

13.

423

Mar;178(3):614-8.

424

14.

425

104 cases. Br J Dermatol. 1968 Dec;80(12):771-93.

426

15.

427

guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed

428

classification of disease severity. Arch Dermatol Res. 2003 Apr;295 Suppl 1:S43-54.

429

16.

430

prevalence of oral mucosal lesions in children and adolescents. Int J Paediatr Dent. 2006

431

Jan;16(1):31-9.

432

17.

433

with geographic tongue. Hum Genet. 2017 Feb;136(2):241-52.

434

18.

435

severe hypocalcaemia due to primary hypoparathyroidism. J Dermatol. 2017 Dec;44(12):1416-7.

436

19.

437

Acute Generalized Pustular Psoriasis of von Zumbusch Triggered by Hypocalcemia. Case Rep

438

Dermatol. 2015 Sep-Dec;7(3):345-51.

439

20.

440

for the management and treatment of generalized pustular psoriasis: The new pathogenesis and

441

treatment of GPP. J Dermatol. 2018 Nov;45(11):1235-70.

442

21.

443

differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019 Mar;143(3):1021-6.

444

22.

445

pustular psoriasis in Sichuan region of China: A case-control study. Medicine (Baltimore). 2018

446

Aug;97(31):e11741.

447

23.

448

majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of

449

interleukin-36 receptor antagonist. J Invest Dermatol. 2013 Nov;133(11):2514-21.

450

24.

451

IL36RN mutation in sibling cases complements our IL36RN mutation statistics for generalized

452

pustular psoriasis. J Dermatol Sci. 2017 Jan;85(1):58-60.

453

25.

454

for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018 Mar;178(3):740-8.

455

26.

456

FMF, Blau, CANDLE. Dermatol Clin. 2013 Jul;31(3):387-404.

457

27.

458

generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular

Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018

Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of

Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, et al. Therapeutic

Furlanetto DL, Crighton A, Topping GV. Differences in methodologies of measuring the

Liang J, Huang P, Li H, Zhang J, Ni C, Wang Y, et al. Mutations in IL36RN are associated

Knuever J, Tantcheva-Poor I. Generalized pustular psoriasis: A possible association with

Guerreiro de Moura CA, de Assis LH, Goes P, Rosa F, Nunes V, Gusmao IM, et al. A Case of

Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines

Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic

Li Z, Yang Q, Wang S. Genetic polymorphism of IL36RN in Han patients with generalized

Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The

Takeichi T, Togawa Y, Okuno Y, Taniguchi R, Kono M, Matsue H, et al. A newly revealed

Mossner R, Wilsmann-Theis D, Oji V, Gkogkolou P, Lohr S, Schulz P, et al. The genetic basis

Tripathi SV, Leslie KS. Autoinflammatory diseases in dermatology: CAPS, TRAPS, HIDS,

Kardaun SH, Kuiper H, Fidler V, Jonkman MF. The histopathological spectrum of acute

26

27

459

psoriasis. J Cutan Pathol. 2010 Dec;37(12):1220-9.

460

28.

461

mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with

462

both AGEP and generalized pustular psoriasis. JAMA Dermatol. 2015 Apr;151(4):452-3.

463

29.

464

Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three

465

Refractory Patients. Ther Apher Dial. 2015 Aug;19(4):336-41.

466

30.

467

of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III

468

open-label multicenter Japanese study. J Dermatol. 2016 Sep;43(9):1011-7.

469

31.

470

term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized

471

pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad

472

Dermatol Venereol. 2019 Feb;33(2):325-32.

473

32.

474

safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma:

475

results from a 52-week, open-label study. Br J Dermatol. 2017 Mar;176(3):741-51.

476

33.

477

treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3

478

study. J Dermatol. 2018 Dec;45(12):1371-80.

479

34.

480

interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and

481

erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label

482

study. J Dermatol. 2018 May;45(5):529-39.

483

35.

484

treatment of generalized pustular psoriasis: a case series. Dermatology. 2008;216(4):355-60.

485

36.

486

Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004 Apr;13(4):193-

487

222.

488

37.

489

specific targeted immunotherapy, systematic review. Exp Dermatol. 2018 Oct;27(10):1067-77.

490

38.

491

Emerging Therapeutic Trend. Cureus. 2016 Jun 22;8(6):e652.

492

39.

493

Infliximab in a Patient With Inflammatory Bowel Disease. J Cutan Med Surg. 2018

494

Sep/Oct;22(5):507-10.

495

40.

Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense

Fujisawa T, Suzuki S, Mizutani Y, Doi T, Yoshida S, Ogura S, et al. Granulocyte and

Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety

Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, Torisu-Itakura H, Morisaki Y, et al. Long-

Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study G. Efficacy and

Morita A, Yamazaki F, Matsuyama T, Takahashi K, Arai S, Asahina A, et al. Adalimumab

Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human

Esposito M, Mazzotta A, Casciello C, Chimenti S. Etanercept at different dosages in the

Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK, 3rd.

Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for

Saikaly SK, Mattes M. Biologics and Pediatric Generalized Pustular Psoriasis: An

Almutairi D, Sheasgreen C, Weizman A, Alavi A. Generalized Pustular Psoriasis Induced by

Viguier M, Aubin F, Delaporte E, Pages C, Paul C, Beylot-Barry M, et al. Efficacy and safety

27

28

496

of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012

497

Dec;148(12):1423-5.

498

41.

499

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients

500

without IL36RN mutations. J Dermatol. 2018 Jul;45(7):850-4.

501

42.

502

Characterization of Interleukin 17A Expression in Subtypes of Psoriasis. J Drugs Dermatol. 2015

503

Oct;14(10):1133-6.

504

43.

505

Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019

506

Mar 7;380(10):981-3.

507

44.

508

Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 Oct 4;379(14):1313-21.

509

45.

510

diseases. J Allergy Clin Immunol. 2017 Dec;140(6):1545-7.

511

46.

512

diseases: An emerging concept encompassing various inflammatory keratinization disorders of the

513

skin. J Dermatol Sci. 2018 May;90(2):105-11.

514

47.

515

keratinization disease. J Dermatol. 2019 Apr;46(4):e125-e6.

516

48.

517

generalized pustular psoriasis and geographic tongue had a heterozygous IL36RN mutation and

518

IgG2 deficiency. J Dermatol Sci. 2018 May;90(2):216-8.

519

49.

520

autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2019 Feb;143(2):809-10.

521

50.

522

pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J

523

Invest Dermatol. 2013 May;133(5):1366-9.

524

51.

525

and update on treatment. J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1645-51.

526

52.

527

mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy

528

Clin Immunol. 2015 Apr;135(4):1067-70 e9.

529

53.

530

Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status. JAMA

531

Dermatol. 2016 Jul 1;152(7):825-8.

532

54.

Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, Bieber T, Schon MP, Huffmeier U, et al.

Lee E, Zarei M, LaSenna C, Villada G, Romanelli P. Psoriasis Targeted Therapy:

Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the

Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P, et al. Phase 2 Trial of

Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization

Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization

Takeichi T, Akiyama M. Familial or sporadic porokeratosis as an autoinflammatory

Oi R, Takeichi T, Okuno Y, Kojima D, Sugawara K, Kono M, et al. An infant with

Akiyama M. Early-onset generalized pustular psoriasis is representative of

Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, et al. Rare

Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review

Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JI, et al. IL36RN

Arakawa A, Ruzicka T, Prinz JC. Therapeutic Efficacy of Interleukin 12/Interleukin 23

Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are

28

29

533

dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017 Jul;140(1):109-

534

20.

535

55.

536

Chemokine Receptor Inhibition in Treating IL-36alpha-Induced Psoriasiform Inflammation. J

537

Immunol. 2019 Mar 15;202(6):1687-92.

538

56.

539

mutations in CARD14. Am J Hum Genet. 2012 May 4;90(5):784-95.

540

57.

541

pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012 Jul 13;91(1):163-

542

70.

543

58.

544

Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations. JAMA Dermatol. 2017 Jan

545

1;153(1):66-70.

546

59.

547

skin autoinflammation in generalized pustular psoriasis via activating keratinocytes. FASEB J. 2019

548

Jun;33(6):6813-28.

549

60.

550

Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating

551

IL-36 Production. J Invest Dermatol. 2016 Nov;136(11):2251-9.

Campbell JJ, Ebsworth K, Ertl LS, McMahon JP, Wang Y, Yau S, et al. Efficacy of

Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, et al. PSORS2 is due to

Fuchs-Telem D, Sarig O, van Steensel MA, Isakov O, Israeli S, Nousbeck J, et al. Familial

Takeichi T, Sugiura K, Nomura T, Sakamoto T, Ogawa Y, Oiso N, et al. Pityriasis Rubra

Shao S, Fang H, Zhang J, Jiang M, Xue K, Ma J, et al. Neutrophil exosomes enhance the

Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, et al. AP1S3

552

29

...